3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
18
NIH
3
NETWORK
2
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
3
Skin Diseases
2
Neoplasms by Site
2
Carcinoma, Renal Cell
2
Uveal Melanoma
1
Uterine Neoplasms
1
Uterine Diseases
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Uterine Cervical Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Prostatic Neoplasms
1
Precancerous Conditions
1
Neoplasm Metastasis
1
Kidney Neoplasms
1
Hematologic Diseases
1
Genital Neoplasms, Female
1
Genital Diseases, Female
1
Genital Diseases
1
Female Urogenital Diseases and Pregnancy Complications
1
Communicable Diseases
1
Breast Neoplasms
1
Breast Diseases
1
Autoimmune Diseases
1
Interventions
Prednisone
103
enzalutamide
76
Docetaxel
72
Abiraterone Acetate
68
Leuprolide
47
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
45
abiraterone
39
apalutamide
29
Prednisolone
27
bicalutamide
26
Zoledronic Acid
24
radium Ra 223 dichloride
22
pembrolizumab
22
darolutamide
22
Goserelin
22
Triptorelin Pamoate
17
cabazitaxel
16
Androgen Antagonists
15
sipuleucel-T
13
luprolide acetate gel depot
12
Injections
12
Dexamethasone
12
olaparib
11
gallium 68 PSMA-11
10
Mitoxantrone
10
Pluvicto
9
Ipilimumab
9
Dutasteride
9
Cyclophosphamide
9
relugolix
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Prostatic Neoplasms
×
Watchful Waiting
×
Clear all
NCT02799745
2024-12-06
ENACT
Astellas Pharma Inc
Phase 2
Completed
227 enrolled
24 charts